CA-ENLIGHTED
16.7.2020 12:02:06 CEST | Business Wire | Press release
Enlighted , the leading building IoT platform provider, expands its award-winning IoT technology with workplace digital contact tracing to help employees return safely to manufacturing facilities, pharmaceutical labs, offices and more. Safe provides digital contact history for employees who self-report testing positive for COVID-19 to help reduce the spread of infection, keep healthy employees safe and productive, and eliminate the tedious, expensive and error-prone manual contact tracing process for employers.
The solution prioritizes data privacy without the need for storing personal information. Employees are assigned alphanumeric ID badges while entering the workplace. When an employee self-reports their badge ID and a positive test result, administrators query the Safe application, identify other IDs this badge came in contact with and share the anonymous IDs. Employees carrying those badge IDs can self-identify their exposure.
The Enlighted solution provides employers with location and proximity data to identify who an infected employee came in contact with inside the workplace, for how long and what areas they visited. The data is used to inform employees who might be at risk of infection and also drives sanitization efforts in areas the infected employee utilized. The application’s dashboard provides information on contacts in the building to assist management in developing safer workplace strategies. Additionally, Safe identifies how many close contacts are happening in a time period and location to proactively manage risk.
Enlighted is in a unique position to provide proven safer workplace solutions for COVID-19 and beyond with its IoT technology already installed in 320 million square feet of buildings globally. Existing customers can simply add the Safe app to their IoT platform. New customers can install the Enlighted IoT system through sensors in LED lighting or through the new USB-powered surface sensor , which can be easily applied under desks or in conference rooms.
“The important role of IoT technology in buildings has been further magnified by the COVID-19 pandemic,” said Stefan Schwab, CEO of Enlighted, a Siemens company. “The Enlighted sensory system can now provide digital contact tracing. It also lays the foundation for future-proofed buildings ready to help us understand with real-time data the changing nature of our at-work experiences and meet challenges beyond COVID-19.”
Enlighted offers a suite of data-driven safer workplace solutions , assisting planners in preparing and executing physical distancing processes, enhanced sanitization and monitoring, occupancy limits and now contact tracing. The IoT platform also integrates through APIs with third-party systems to provide touchless entry, smart desk hoteling, conference room booking and more.
The Safe application is available immediately for new and existing Enlighted customers. Visit www.enlightedinc.com/contact-sales to talk with a sales representative or request a demonstration, or visit http://www.enlightedinc.com to learn about Enlighted’s full suite of workplace safety solutions.
ABOUT ENLIGHTED
Designed to change everything, Enlighted provides the world’s most advanced Building IoT Platform for leading commercial and healthcare organizations around the globe, with more than 320 million square feet of building space deployed to date. Founded in 2009 and headquartered in Silicon Valley, Enlighted was acquired in 2018 and is a wholly-owned subsidiary of Siemens Industry, Inc. as part of Siemens Smart Infrastructure. For more information about Enlighted, visit enlightedinc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200716005237/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
